Patrick J. Heron - Mar 10, 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role: Director
Signature: /s/ Steve R. Bailey, Attorney-in-Fact For Patrick J. Heron
Stock symbol: MIRM
Transactions as of: Mar 10, 2025
Transactions value $: $99,518
Form type: 4
Date filed: 3/12/2025, 04:51 PM
Previous filing: Mar 10, 2025
Next filing: Mar 18, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MIRM	Common Stock	Purchase	$32.3K	+758	+0.46%	$42.66	167K	Mar 10, 2025	By Frazier Life Sciences X, L.P.	F1, F2
transaction	MIRM	Common Stock	Purchase	$25K	+577	+0.35%	$43.37	167K	Mar 10, 2025	By Frazier Life Sciences X, L.P.	F2, F3
transaction	MIRM	Common Stock	Purchase	$42.2K	+963	+0.58%	$43.77	168K	Mar 11, 2025	By Frazier Life Sciences X, L.P.	F2, F4
holding	MIRM	Common Stock						3.57M	Mar 10, 2025	By Frazier Life Sciences IX, L.P.	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $43.42 to $43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (3) and (4) to this Form 4.
F2	The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F3	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $43.20 to $43.50, inclusive.
F4	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $43.405 to $44, inclusive.
F5	The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. The Reporting Person is one of two managing members of FHMLS IX, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.